title: TNF-α Antagonist and Vascular Inflammation in Patients with Psoriasis Vulgaris: A Randomized Placebo-Controlled Study.
abstract: Vascular inflammation is increased in patients with psoriasis. This randomized, double-blind, multicenter study evaluated the effects of tumor necrosis factor-α antagonist adalimumab on vascular inflammation in patients with psoriasis. A total of 107 patients were randomized (1:1) to receive adalimumab for 52 weeks or placebo for 16 weeks followed by adalimumab for 52 weeks. Vascular inflammation was assessed with positron emission tomography-computed tomography. There were no differences in the change from baseline in vessel wall target-to-background ratio (TBR) from the ascending aorta (primary endpoint) (adalimumab: TBR = 0.002, 95% confidence interval [CI] = -0.048 to 0.053; placebo: TBR = -0.002, 95% CI = -0.053 to 0.049; P = 0.916) and the carotids (adalimumab: TBR = 0.031, 95% CI = -0.005 to 0.066; placebo: TBR = 0.018, 95% CI = -0.019 to 0.055; P = 0.629) at week 16 between adalimumab and placebo. After 52 weeks of treatment with adalimumab there was no significant change from start of treatment in TBR from the ascending aorta (TBR = -0.006, 95% CI = -0.049 to 0.038; P = 0.796), but there was an increase in TBR in carotids (TBR = 0.027, 95% CI = 0.000 to 0.054; P = 0.046). This study showed no difference over 16 weeks in vascular inflammation in patients treated with a tumor necrosis factor-α antagonist or placebo and a modest increase in vascular inflammation in carotids after 52 weeks of treatment with adalimumab.
authors.affiliation: Innovaderm Research, Incorporated, Montreal, Quebec, Canada. Electronic address: rbissonnette@innovaderm.ca.
authors.forename: Robert
authors.initials: R
authors.lastname: Bissonnette
authors.affiliation: Montreal Heart Institute Research Center, Université de Montréal, Montreal, Quebec, Canada.
authors.forename: François
authors.initials: F
authors.lastname: Harel
authors.affiliation: Laboratory of Investigative Dermatology, Rockefeller University, New York, New York, USA.
authors.forename: James G
authors.initials: JG
authors.lastname: Krueger
authors.affiliation: Montreal Health Innovations Coordinating Center (MHICC), Montreal, Quebec, Canada.
authors.forename: Marie-Claude
authors.initials: MC
authors.lastname: Guertin
authors.affiliation: Montreal Health Innovations Coordinating Center (MHICC), Montreal, Quebec, Canada.
authors.forename: Malorie
authors.initials: M
authors.lastname: Chabot-Blanchet
authors.affiliation: Laboratory of Investigative Dermatology, Rockefeller University, New York, New York, USA.
authors.forename: Juana
authors.initials: J
authors.lastname: Gonzalez
authors.affiliation: Innovaderm Research, Incorporated, Montreal, Quebec, Canada.
authors.forename: Catherine
authors.initials: C
authors.lastname: Maari
authors.affiliation: Dr Isabelle Delorme, Incorporated, Drummondville, Quebec, Canada.
authors.forename: Isabelle
authors.initials: I
authors.lastname: Delorme
authors.affiliation: Lynderm Research, Incorporated, Markham, Ontario, Canada.
authors.forename: Charles W
authors.initials: CW
authors.lastname: Lynde
authors.affiliation: Montreal Heart Institute Research Center, Université de Montréal, Montreal, Quebec, Canada.
authors.forename: Jean-Claude
authors.initials: JC
authors.lastname: Tardif
mesh_terms: D000068879:Adalimumab / Q000008:administration & dosage*; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage; D001013:Aorta, Thoracic / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007249:Inflammation / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D013997:Time Factors; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000378:metabolism
chemical_list: D000893:Anti-Inflammatory Agents; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab